Circular solution of two unequal mass particles in post-Minkowski approximation

A Fokker action for post-Minkowski approximation with the first post-Newtonian correction is introduced in our previous paper, and a solution for the helically symmetric circular orbit is obtained. We present supplemental results for the circular solution of two unequal mass point-particles. Circular solutions for selected mass ratios are found numerically, and analytic formulas in the extreme mass ratio limit are derived. The leading terms of the analytic formulas agree with the first post-Newtonian formulas in this limit.Comment: 4 pages, 4 figures, 4/27/0

Intensified bioprocessing enabling single-use technologies

more than a decade ago to the new state-of-the-art. The successful adoption of single use continues to be driven by the industry seeking for more flexible and cost-effective production platforms. In recent years, the rise of biosimilars and multiple drug entities becoming available for similar diseases has significantly increased the pressure on manufacturing costs. At the same time, production is more and more shifting towards smaller batches in highly flexible multiproduct facilities to adapt to the rapid and dynamically changing market demands. Driven by these needs, the industry has witnessed an upsurge of interest in intensified and continuous bioprocessing. Many companies are developing integrated continuous bioprocessing platforms by leveraging existing technology and combining it with novel, innovative single-use solutions. Intensified processing and single‑use technology thereby go hand-in-hand: continuous or intensified operation reduces the overall size of the manufacturing equipment which enables single-use technology in steps where the sheer size of an equipment has previously been a limiting factor. Instead of processing drug material as one single, large batch, an intensified platform moves the product through integrated unit operations either at a continuously low flow or in cycles of smaller sub-lots. Additionally, in intensified manufacturing, a carefully sized equipment enables producers to utilize it to produce various batch sizes and decrease the labor, costs, time and risks for up- or downscaling. A variety of fully continuous or hybrid batch/continuous manufacturing platforms for biologics have been created thus far, all of them predominantly based on single-use technologies. In these platforms, the focus of process intensification lies on four aspects: 1) the primary product flow, 2) the materials and buffer flow, 3) flow of information and 4) portability (scaling and Tech Transfer). A multitude of concepts and technologies have been successfully implemented to intensify the primary product flow, including perfusion upstream platforms, multicolumn chromatography systems, continuous virus inactivation and high-performance chromatography sorbents or membranes. In addition, the material and buffer preparations are a significant and often underrated contributor to process optimization. The recently developed single-use buffer management systems dilute process buffers from concentrates for the entire downstream platform both at point of use and just in time. Intensified processing has gained traction in the industry. Data from early adopters is promising, with first manufacturers moving their integrated platforms into cGMP environments. The ongoing adoption of intensified and continuous manufacturing concepts is enabling a more widespread use of single-use technology. In combination, the two concepts are a powerful and mutually enabling duo that may permit the biopharmaceutical industry to deliver essential drugs to larger patient populations at lower cost. Please click Additional Files below to see the full abstract

Contemporary Treatment Options for Pulmonary Embolism

Purpose: Provide RNs education on the classifications of PEs and new catheter directed treatment options. Significance: PE remains a common and lethal entity PE is the 3rd leading cause of cardiovascular death in hospitalized patients (60,000-1000,000 per year) 150,000-250,000 PE related hospitalizations per year RNs must be knowledgeable of the classifications of PEs and catheter directed therapies to promote positive patient outcomes Prior to catheter directed therapies, submassive PEs had a mortality rate up to 20% at 3 months and were traditionally treated with IV heparin, or oral anticoagulant therapyhttps://digitalcommons.centracare.com/nursing_posters/1139/thumbnail.jp

It\u27s Time to Break Old Habits: Admitting STEMIs to the Telemetry Unit

Beginning December 2020 uncomplicated ST-Elevated MI patients will be admitted directly to Telemetry following intervention instead of CICU. June 2020: Review and develop evidence- based exclusion criteria for admission to Telemetry June 2020: Create a process for communication between the nursing supervisor, cath lab, Telemetry Unit and CICU for patient placement Fall 2020: Meeting with Telemetry and CICU charge nurse, nursing supervisor and cath lab RN to discuss communication process Dec 2020: Begin tracking STEMI patients Unit admitted to (Telemetry or CICU/ICU) Requiring transfer to CICU/ICU from Telemetryhttps://digitalcommons.centracare.com/nursing_posters/1120/thumbnail.jp